Messika-Zeitoun David, Burwash Ian G, Mesana Thierry
University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Echo Res Pract. 2019 Dec 1;6(4):T1-T6. doi: 10.1530/ERP-19-0041.
Valvular heart disease (VHD) is responsible for a major societal and economic burden. Incidence and prevalence of VHD are high and increase as the population ages, creating the next epidemic. In Western countries, the etiology is mostly degenerative or functional disease and strikes an elderly population with multiple comorbidities. Epidemiological studies have shown that VHD is commonly underdiagnosed, leading to patients presenting late in their disease course, to an excess risk of mortality and morbidity and to a missed opportunity for intervention. Once diagnosed, VHD is often undertreated with patients unduly denied intervention, the only available curative treatment. This gap between current recommendations and clinical practice and the marked under-treatment is at least partially related to poor knowledge of current National and International Societies Guidelines. Development of a valvular heart team involving multidisciplinary valve specialists including clinicians, imaging specialists, interventional cardiologists and surgeons is expected to fill these gaps and to offer an integrated care addressing all issues of patient management from evaluation, risk-assessment, decision-making and performance of state-of-the-art surgical and transcatheter interventions. The valvular heart team will select the right treatment for the right patient, improving cost-effectiveness and ultimately patients' outcomes.
心脏瓣膜病(VHD)造成了重大的社会和经济负担。VHD的发病率和患病率很高,且随着人口老龄化而上升,形成下一场流行病。在西方国家,其病因大多是退行性或功能性疾病,侵袭患有多种合并症的老年人群。流行病学研究表明,VHD常常未被诊断出来,导致患者在疾病进程后期才就诊,增加了死亡和发病风险,也错失了干预时机。一旦确诊,VHD往往治疗不足,患者被不恰当地拒绝接受唯一可用的治愈性治疗——干预。当前建议与临床实践之间的这种差距以及显著的治疗不足至少部分与对当前国家和国际学会指南的了解不足有关。组建一个由包括临床医生、影像专家、介入心脏病专家和外科医生在内的多学科瓣膜专家组成的心脏瓣膜团队,有望填补这些差距,并提供综合护理,解决从评估、风险评估、决策到实施最先进的外科和经导管干预等患者管理的所有问题。心脏瓣膜团队将为合适的患者选择合适的治疗方法,提高成本效益,并最终改善患者的治疗效果。